Phibro Animal Health Corporation Net Assets
Phibro Animal Health Corporation net assets. Based on the latest financial reports, Phibro Animal Health Corporation (PAHC) has net assets worth $385.48 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.50 Billion) and total liabilities ($1.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Phibro Animal Health Corporation balance sheet quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $385.48 Million |
| % of Total Assets | 25.68% |
| Annual Growth Rate | 10.09% |
| 5-Year Change | 46.88% |
| 10-Year Change | 155.02% |
| Growth Volatility | 500.96 |
Net Assets of Phibro Animal Health Corporation (2000–2026)
Net assets of Phibro Animal Health Corporation from 2000 to 2026. This chart illustrates how Phibro Animal Health Corporation's net assets have evolved over time, based on quarterly financial data. Also explore how fast is Phibro Animal Health Corporation growing its equity to track the company's year-over-year net asset growth rate.
Annual Net Assets for Phibro Animal Health Corporation (2000–2026)
The table below shows the annual net assets of Phibro Animal Health Corporation from 2000 to 2026. For live market cap and overall valuation, see PAHC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | $385.48 Million | +34.93% |
| 2025-06-30 | $285.68 Million | +11.32% |
| 2024-06-30 | $256.64 Million | -9.16% |
| 2023-06-30 | $282.51 Million | +7.65% |
| 2022-06-30 | $262.44 Million | +10.03% |
| 2021-06-30 | $238.53 Million | +26.74% |
| 2020-06-30 | $188.20 Million | -12.87% |
| 2019-06-30 | $216.01 Million | +16.79% |
| 2018-06-30 | $184.95 Million | +22.36% |
| 2017-06-30 | $151.16 Million | +67.06% |
| 2016-06-30 | $90.48 Million | +205.39% |
| 2015-06-30 | $29.63 Million | +95.58% |
| 2014-06-30 | $15.15 Million | +121.97% |
| 2013-06-30 | $-68.94 Million | +21.86% |
| 2012-06-30 | $-88.23 Million | -63.76% |
| 2009-06-30 | $-53.88 Million | -40.33% |
| 2008-06-30 | $-38.39 Million | +56.37% |
| 2007-06-30 | $-88.00 Million | -5.14% |
| 2006-06-30 | $-83.70 Million | -86.41% |
| 2005-06-30 | $-44.90 Million | +29.62% |
| 2004-06-30 | $-63.80 Million | +24.59% |
| 2003-06-30 | $-84.60 Million | -38.24% |
| 2002-06-30 | $-61.20 Million | -1900.00% |
| 2001-06-30 | $3.40 Million | -89.27% |
| 2000-06-30 | $31.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phibro Animal Health Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 976.1% over the analyzed period, indicating profitable operations and earnings retention.
Phibro Animal Health Corporation Net Assets Breakdown (June 2026)
Phibro Animal Health Corporation net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $352.96 Million | 91.56% |
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $-106.08 Million | -27.52% |
| Other Components | $138.59 Million | 35.95% |
| Total Equity | $385.48 Million | 100.00% |
Phibro Animal Health Corporation Competitors by Market Cap
The table below lists competitors of Phibro Animal Health Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Otokar Otomotiv ve Savunma Sanayi AS
IS:OTKAR
|
$819.07 Million |
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
$819.27 Million |
|
Jolywood Suzhou Sunwatt Co Ltd
SHE:300393
|
$819.56 Million |
|
Zhejiang Hailide New Material Co Ltd
SHE:002206
|
$819.73 Million |
|
Guangdong Tonze Electric Co Ltd
SHE:002759
|
$818.79 Million |
|
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-A
|
$818.75 Million |
|
Douglas AG
XETRA:DOU
|
$818.46 Million |
|
York Space Systems Inc.
NYSE:YSS
|
$818.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phibro Animal Health Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 285,682,000 to 385,477,000, a change of 99,795,000 (34.9%).
- Net income of 99,720,000 contributed positively to equity growth.
- Dividend payments of 19,463,000 reduced retained earnings.
- Other comprehensive income increased equity by 17,941,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $99.72 Million | +25.87% |
| Dividends Paid | $19.46 Million | -5.05% |
| Other Comprehensive Income | $17.94 Million | +4.65% |
| Other Changes | $1.60 Million | +0.41% |
| Total Change | $- | 34.93% |
Book Value vs Market Value Analysis
This analysis compares Phibro Animal Health Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 73.67x to 4.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | $0.53 | $38.80 | x |
| 2001-06-30 | $0.06 | $38.80 | x |
| 2002-06-30 | $-1.02 | $38.80 | x |
| 2003-06-30 | $-1.41 | $38.80 | x |
| 2004-06-30 | $-1.06 | $38.80 | x |
| 2005-06-30 | $-0.75 | $38.80 | x |
| 2006-06-30 | $-1.40 | $38.80 | x |
| 2007-06-30 | $-2.27 | $38.80 | x |
| 2008-06-30 | $-0.99 | $38.80 | x |
| 2009-06-30 | $-1.39 | $38.80 | x |
| 2012-06-30 | $-2.89 | $38.80 | x |
| 2013-06-30 | $-2.26 | $38.80 | x |
| 2014-06-30 | $0.47 | $38.80 | x |
| 2015-06-30 | $0.74 | $38.80 | x |
| 2016-06-30 | $2.26 | $38.80 | x |
| 2017-06-30 | $3.78 | $38.80 | x |
| 2018-06-30 | $4.58 | $38.80 | x |
| 2019-06-30 | $5.33 | $38.80 | x |
| 2020-06-30 | $4.65 | $38.80 | x |
| 2021-06-30 | $5.89 | $38.80 | x |
| 2022-06-30 | $6.48 | $38.80 | x |
| 2023-06-30 | $6.97 | $38.80 | x |
| 2024-06-30 | $6.33 | $38.80 | x |
| 2025-06-30 | $7.02 | $38.80 | x |
| 2026-06-30 | $9.40 | $38.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phibro Animal Health Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 25.87%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.57%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 3.89x
- Recent ROE (25.87%) is above the historical average (3.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 31.96% | 3.13% | 1.25x | 8.18x | $6.94 Million |
| 2001 | -438.24% | -4.66% | 0.97x | 97.06x | $-15.24 Million |
| 2002 | 0.00% | -15.76% | 1.11x | 0.00x | $-45.68 Million |
| 2003 | 0.00% | -5.21% | 1.23x | 0.00x | $-9.15 Million |
| 2004 | 0.00% | 3.64% | 1.47x | 0.00x | $19.28 Million |
| 2005 | 0.00% | -6.06% | 1.44x | 0.00x | $-17.61 Million |
| 2006 | 0.00% | -3.29% | 1.60x | 0.00x | $-4.72 Million |
| 2007 | 0.00% | -1.48% | 1.67x | 0.00x | $2.10 Million |
| 2008 | 0.00% | 0.43% | 1.57x | 0.00x | $6.04 Million |
| 2009 | 0.00% | -1.55% | 1.49x | 0.00x | $-2.91 Million |
| 2012 | 0.00% | 1.07% | 1.48x | 0.00x | $15.80 Million |
| 2013 | 0.00% | 3.81% | 1.38x | 0.00x | $31.78 Million |
| 2014 | -20.46% | -0.45% | 1.46x | 31.18x | $-4.61 Million |
| 2015 | 203.46% | 8.05% | 1.52x | 16.65x | $57.32 Million |
| 2016 | 91.40% | 11.00% | 1.23x | 6.75x | $73.65 Million |
| 2017 | 42.74% | 8.45% | 1.23x | 4.12x | $49.48 Million |
| 2018 | 35.09% | 7.91% | 1.22x | 3.63x | $46.40 Million |
| 2019 | 25.32% | 6.61% | 1.14x | 3.36x | $33.10 Million |
| 2020 | 17.83% | 4.19% | 1.02x | 4.17x | $14.73 Million |
| 2021 | 22.80% | 6.53% | 0.99x | 3.53x | $30.53 Million |
| 2022 | 18.74% | 5.22% | 1.01x | 3.55x | $22.93 Million |
| 2023 | 11.54% | 3.33% | 1.01x | 3.44x | $4.36 Million |
| 2024 | 0.94% | 0.24% | 1.04x | 3.83x | $-23.25 Million |
| 2025 | 16.89% | 3.72% | 0.95x | 4.76x | $19.70 Million |
| 2026 | 25.87% | 6.57% | 1.01x | 3.89x | $61.17 Million |
Industry Comparison
This section compares Phibro Animal Health Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $179,918,493
- Average return on equity (ROE) among peers: -17.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phibro Animal Health Corporation (PAHC) | $385.48 Million | 31.96% | 2.89x | $818.90 Million |
| Aurora Cannabis Inc (ACB) | $1.62 Million | -9.01% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $-202.64 Million | 0.00% | 0.00x | $143.73 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $546.25K |
| Akebia Ther (AKBA) | $247.62 Million | -141.29% | 1.60x | $151.89 Million |
| Alkermes Plc (ALKS) | $161.37 Million | -10.45% | 1.50x | $7.32 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.03 Billion |
| Amphastar P (AMPH) | $251.54 Million | 4.72% | 0.35x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $356.74 Million | 25.53% | 10.23x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $210.85 Million | 14.59% | 0.12x | $279.44 Million |
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including po… Read more